I love picking up bargain FTSE 100 shares after they’ve suffered a short, sharp sell-off. Two stocks on my watchlist are now in that exact position. Should I buy them?
The first is pharmaceuticals giant AstraZeneca (LSE: AZN). I’ve been desperate to buy its shares for yonks, but decided they were too expensive after repeated long-term outperformance.
Suddenly, and to my surprise, the AstraZeneca share price is down 11.88% in the last month. So what sparked the sell-off?
What’s gone wrong?
The shares boomed for years as CEO Pascal Soriot successfully replenished the company’s drugs pipeline. However, in September, it’s suffered a couple of setbacks as a new lung cancer and breast cancer treatment both underwhelmed. The results overshadowed successes elsewhere, including US approval for its Fasenra inflammatory disease drug.
Pharmaceutical companies will always have their share of successes and failures, but a long-term investor like me can look past them.
What I’m still struggling to look past is that the shares trade at 35.01 times earnings, well above the average FTSE 100 valuation of around 15.3 times. According to its discounted cash flow (DCF) ratio, they’re overvalued by 7%.
I won’t quibble too much about the relatively low 2.03% yield, that’s largely down to the booming share price. The stock’s up just 5.6% over one year, but almost 60% over five years.
There’s so much to like about AstraZeneca, including gross margins of 75.69%, and a 16.83% return on equity. But it isn’t a blinding bargain, so I’ll wait to see if it gets a bit cheaper.
Housebuilder Barratt Developments (LSE: BDEV) has also had a rocky month, its shares falling 10.35%. Over one year, they’re up just 5.98%.
So what’s up with Barratt? Isn’t the sector supposed to be booming in anticipation of falling interest rates and Labour’s house-building spree?
Barratt is also heading south
Barratt’s gearing up for that by forming a master developer platform with UK government agency Homes England and Lloyds Bank, which will focus on large building sites.
That’s all in the future though. On 4 September, Barratt reported a 75% plunge in full-year profits from £705m to just £170.5m. It pinned that on cost-of-living pressures, higher mortgage rates and low consumer confidence. Completions fell 18.6% to 14,000, although this was at the upper end of expectations. It’ll build even fewer homes in 2025.
Now here’s the killer. It halved the annual dividend to just 16.2p a share. Adding to the uncertainty, it’s pressing ahead on with its £2.5bn takeover of rival Redrow, despite competition concerns.
Given the problems, I’d hoped Barratt’s shares would be cheaper. Today’s trailing P/E of 17.48 times earnings doesn’t blow me away. And while the trailing yield’s a blockbuster 6.89%, it’s forecast to fall to just 3.21% next year.
I’m also worried that Labour will struggle to turn its housebuilding dream into a reality. So I won’t buy Barratt either. I can see much better value elsewhere on today’s FTSE 100.
The post 2 of my favourite FTSE 100 shares have just plunged 12% and 10%! Time to buy? appeared first on The Motley Fool UK.
Should you buy AstraZeneca now?
Don’t make any big decisions yet.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.
And he believes they could bring spectacular returns over the next decade.
Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows…
When such enormous changes hit a big industry, informed investors can potentially get rich.
So, with his new report, Mark’s aiming to put more investors in this enviable position.
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
As AstraZeneca’s share price drops 13% should I buy on the dip?
3 stunning FTSE 100 shares I plan to buy in October
As new homes initiatives are launched, is now the time to buy this big FTSE housebuilder?
This UK stock looks pretty cheap to me
4 heavily shorted UK stocks that Fools think could be great long-term investments!
Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
